RANDAL J KIRK Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for RANDAL J KIRK.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of RANDAL J KIRK. RANDAL J KIRK is Director in CLINICAL DATA INC ($NOVI) and 10% Owner in HALOZYME THERAPEUTICS INC ($GYHT) and Director in HALOZYME THERAPEUTICS INC ($GYHT) and Chairman, President and CEO in NEW RIVER PHARMACEUTICALS INC ($NRPH).
Latest Insider Trading Transactions of RANDAL J KIRK
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, NOVI, GYHT, NRPH
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Sep 20 2010 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Grant | A | 0.00 | 15,200 | 0 | 2,326,687 | 2.3 M to 2.3 M (+0.66 %) |
May 10 2010 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Grant | A | 0.00 | 20,000 | 0 | 3,410,000 | 3.4 M to 3.4 M (+0.59 %) |
Sep 21 2009 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Grant | A | 0.00 | 18,000 | 0 | 2,311,487 | 2.3 M to 2.3 M (+0.78 %) |
May 08 2009 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Grant | A | 0.00 | 20,000 | 0 | 3,390,000 | 3.4 M to 3.4 M (+0.59 %) |
Feb 27 2009 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Option Exercise | P | 8.18 | 3,055,300 | 24,999,992 | 3,055,300 | |
Feb 27 2009 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Option Exercise | P | 8.18 | 3,055,300 | 24,999,992 | 3,055,300 | |
Feb 27 2009 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Option Exercise | P | 9.74 | 763,825 | 7,442,711 | 763,825 | |
Feb 27 2009 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Option Exercise | P | 9.74 | 763,825 | 7,442,711 | 763,825 | |
Feb 27 2009 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Option Exercise | P | 8.12 | 763,825 | 6,202,259 | 763,825 | |
Feb 27 2009 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Option Exercise | P | 8.12 | 763,825 | 6,202,259 | 763,825 | |
Jul 14 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Option Exercise | X | 1.75 | 136,300 | 238,525 | 0 | |
Jul 14 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | X | 1.75 | 136,300 | 238,525 | 1,436,186 | 1.3 M to 1.4 M (+10.49 %) |
Sep 30 2008 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Option Exercise | A | 16.44 | 12,120 | 199,253 | 12,120 | |
Sep 30 2008 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Option Exercise | A | 16.44 | 24,239 | 398,489 | 24,239 | |
Sep 30 2008 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Option Exercise | A | 16.44 | 24,239 | 398,489 | 24,239 | |
Sep 30 2008 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Option Exercise | A | 16.44 | 121,194 | 1,992,429 | 121,194 | |
Sep 30 2008 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Option Exercise | A | 16.44 | 60,597 | 996,215 | 60,597 | |
Sep 30 2008 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Option Exercise | A | 16.44 | 302,983 | 4,981,041 | 302,983 | |
Sep 30 2008 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Option Exercise | A | 16.44 | 212,089 | 3,486,743 | 212,089 | |
Sep 30 2008 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Grant | A | 16.50 | 24,240 | 400,021 | 24,240 | 0 to 24.2 K |
Sep 30 2008 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Grant | A | 16.50 | 48,478 | 800,008 | 48,478 | 0 to 48.5 K |
Sep 30 2008 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Grant | A | 16.50 | 48,478 | 800,008 | 48,478 | 0 to 48.5 K |
Sep 30 2008 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Grant | A | 16.50 | 242,388 | 4,000,008 | 242,388 | 0 to 242.4 K |
Sep 30 2008 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Grant | A | 16.50 | 121,194 | 2,000,004 | 183,772 | 62.6 K to 183.8 K (+193.67 %) |
Sep 30 2008 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Grant | A | 16.50 | 605,966 | 9,999,954 | 1,626,722 | 1 M to 1.6 M (+59.36 %) |
Sep 30 2008 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Grant | A | 16.50 | 424,178 | 6,999,997 | 2,063,458 | 1.6 M to 2.1 M (+25.88 %) |
Sep 25 2008 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Grant | A | 0.00 | 18,334 | 0 | 1,639,280 | 1.6 M to 1.6 M (+1.13 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.51 | 1,500 | 8,265 | 1,299,886 | 1.3 M to 1.3 M (+0.12 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.52 | 500 | 2,760 | 1,298,386 | 1.3 M to 1.3 M (+0.04 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.53 | 3,300 | 18,249 | 1,297,886 | 1.3 M to 1.3 M (+0.25 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.55 | 22,344 | 124,009 | 1,294,586 | 1.3 M to 1.3 M (+1.76 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.57 | 819 | 4,562 | 1,272,242 | 1.3 M to 1.3 M (+0.06 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Option Exercise | P | 1.75 | 136,300 | 238,525 | 136,300 | |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.58 | 200 | 1,116 | 1,271,423 | 1.3 M to 1.3 M (+0.02 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.59 | 300 | 1,677 | 1,271,223 | 1.3 M to 1.3 M (+0.02 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.60 | 4,271 | 23,918 | 1,270,923 | 1.3 M to 1.3 M (+0.34 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.61 | 4,200 | 23,562 | 1,266,652 | 1.3 M to 1.3 M (+0.33 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.62 | 10,400 | 58,448 | 1,262,452 | 1.3 M to 1.3 M (+0.83 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.63 | 9,100 | 51,233 | 1,252,052 | 1.2 M to 1.3 M (+0.73 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.64 | 136,761 | 771,332 | 1,242,952 | 1.1 M to 1.2 M (+12.36 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.65 | 13,092 | 73,970 | 1,106,191 | 1.1 M to 1.1 M (+1.20 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.66 | 9,800 | 55,468 | 1,093,099 | 1.1 M to 1.1 M (+0.90 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.67 | 10,808 | 61,281 | 1,083,299 | 1.1 M to 1.1 M (+1.01 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.68 | 6,700 | 38,056 | 1,072,491 | 1.1 M to 1.1 M (+0.63 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.69 | 6,400 | 36,416 | 1,065,791 | 1.1 M to 1.1 M (+0.60 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.70 | 24,100 | 137,370 | 1,059,391 | 1 M to 1.1 M (+2.33 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.71 | 23,504 | 134,208 | 1,035,291 | 1 M to 1 M (+2.32 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.72 | 1,496 | 8,557 | 1,011,787 | 1 M to 1 M (+0.15 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.78 | 5,000 | 28,900 | 1,010,291 | 1 M to 1 M (+0.50 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.79 | 1,200 | 6,948 | 1,005,291 | 1 M to 1 M (+0.12 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.80 | 6,220 | 36,076 | 1,004,091 | 997.9 K to 1 M (+0.62 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.81 | 1,300 | 7,553 | 997,871 | 996.6 K to 997.9 K (+0.13 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.82 | 1,200 | 6,984 | 996,571 | 995.4 K to 996.6 K (+0.12 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.83 | 7,000 | 40,810 | 995,371 | 988.4 K to 995.4 K (+0.71 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.84 | 3,080 | 17,987 | 988,371 | 985.3 K to 988.4 K (+0.31 %) |
Jun 25 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.93 | 427,100 | 2,532,703 | 985,291 | 558.2 K to 985.3 K (+76.52 %) |
Jun 23 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.85 | 175,500 | 1,026,675 | 558,191 | 382.7 K to 558.2 K (+45.86 %) |
Jun 23 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 6.02 | 59,900 | 360,598 | 382,691 | 322.8 K to 382.7 K (+18.56 %) |
Jun 18 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.76 | 36,827 | 212,124 | 322,791 | 286 K to 322.8 K (+12.88 %) |
Jun 18 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.98 | 42,000 | 251,160 | 285,964 | 244 K to 286 K (+17.22 %) |
Jun 18 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.73 | 25,800 | 147,834 | 243,964 | 218.2 K to 244 K (+11.83 %) |
Jun 13 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.53 | 45,725 | 252,859 | 218,164 | 172.4 K to 218.2 K (+26.52 %) |
Jun 13 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.42 | 57,000 | 308,940 | 172,439 | 115.4 K to 172.4 K (+49.38 %) |
Jun 13 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.27 | 115,439 | 608,364 | 115,439 | 0 to 115.4 K |
May 12 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Option Exercise | A | 4.94 | 10,000 | 49,400 | 10,000 | |
May 12 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Grant | A | 0.00 | 15,000 | 0 | 370,000 | 355 K to 370 K (+4.23 %) |
Jun 23 2008 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Buy | P | 16.49 | 5,985 | 98,693 | 3,380,985 | 3.4 M to 3.4 M (+0.18 %) |
Mar 24 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 6.06 | 580,000 | 3,514,800 | 6,328,853 | 5.7 M to 6.3 M (+10.09 %) |
Mar 24 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 6.12 | 684,657 | 4,190,101 | 5,748,853 | 5.1 M to 5.7 M (+13.52 %) |
Mar 20 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.80 | 886,650 | 5,142,570 | 5,064,196 | 4.2 M to 5.1 M (+21.22 %) |
Mar 20 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 4.57 | 207,546 | 948,485 | 4,177,546 | 4 M to 4.2 M (+5.23 %) |
Mar 20 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 5.80 | 886,650 | 5,142,570 | 5,064,196 | 4.2 M to 5.1 M (+21.22 %) |
Mar 20 2008 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 4.57 | 207,546 | 948,485 | 4,177,546 | 4 M to 4.2 M (+5.23 %) |
Oct 03 2007 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Grant | A | 0.00 | 20,460 | 0 | 1,620,946 | 1.6 M to 1.6 M (+1.28 %) |
Sep 20 2007 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 9.00 | 23,085 | 207,765 | 3,970,000 | 3.9 M to 4 M (+0.58 %) |
Sep 20 2007 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 8.87 | 15,489 | 137,387 | 3,946,915 | 3.9 M to 3.9 M (+0.39 %) |
Sep 17 2007 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 8.66 | 238,020 | 2,061,253 | 3,931,426 | 3.7 M to 3.9 M (+6.44 %) |
Sep 17 2007 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 8.71 | 127,693 | 1,112,206 | 3,693,406 | 3.6 M to 3.7 M (+3.58 %) |
Sep 17 2007 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 8.74 | 65,713 | 574,332 | 3,565,713 | 3.5 M to 3.6 M (+1.88 %) |
Jul 19 2007 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Buy | P | 22.00 | 2,250,000 | 49,500,000 | 2,250,000 | 0 to 2.3 M |
Jun 01 2007 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | P | 9.17 | 3,500,000 | 32,095,000 | 3,500,000 | 0 to 3.5 M |
May 17 2007 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Option Exercise | A | 10.37 | 10,000 | 103,700 | 10,000 | |
May 17 2007 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Grant | A | 10.37 | 15,000 | 155,550 | 355,000 | 340 K to 355 K (+4.41 %) |
Jan 31 2007 | NRPH | NEW RIVER PHARMACE ... | KIRK RANDAL J | Chairman, President ... | Option Exercise | A | 56.39 | 298,200 | 16,815,498 | 298,200 | |
Mar 15 2007 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Buy | P | 7.91 | 11,960 | 94,604 | 522,460 | 510.5 K to 522.5 K (+2.34 %) |
Mar 15 2007 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Buy | P | 7.91 | 18,240 | 144,278 | 1,326,320 | 1.3 M to 1.3 M (+1.39 %) |
Mar 15 2007 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Buy | P | 7.93 | 46,080 | 365,414 | 1,308,080 | 1.3 M to 1.3 M (+3.65 %) |
Feb 27 2007 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Option Exercise | X | 19.45 | 13,329 | 259,249 | 0 | |
Feb 27 2007 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Option Exercise | X | 19.45 | 48,252 | 938,501 | 0 | |
Feb 27 2007 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Option Exercise | X | 19.45 | 31,833 | 619,152 | 0 | |
Feb 27 2007 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Option Exercise | X | 19.45 | 37,670 | 732,682 | 0 | |
Feb 27 2007 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Option Exercise | X | 19.45 | 50,400 | 980,280 | 0 | |
Feb 27 2007 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Option Exercise | X | 19.45 | 2,876 | 55,938 | 0 | |
Feb 27 2007 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Buy | X | 19.45 | 13,329 | 259,249 | 193,343 | 180 K to 193.3 K (+7.40 %) |
Feb 27 2007 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Buy | X | 19.45 | 48,252 | 938,501 | 699,918 | 651.7 K to 699.9 K (+7.40 %) |
Feb 27 2007 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Buy | X | 19.45 | 31,833 | 619,152 | 461,745 | 429.9 K to 461.7 K (+7.40 %) |
Feb 27 2007 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Buy | X | 19.45 | 37,670 | 732,682 | 680,504 | 642.8 K to 680.5 K (+5.86 %) |
Feb 27 2007 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Buy | X | 19.45 | 50,400 | 980,280 | 731,083 | 680.7 K to 731.1 K (+7.40 %) |
Feb 27 2007 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Buy | X | 19.45 | 2,876 | 55,938 | 41,719 | 38.8 K to 41.7 K (+7.40 %) |
Nov 13 2006 | NRPH | NEW RIVER PHARMACE ... | KIRK RANDAL J | Chairman, President ... | Sell | S | 48.23 | 35,284 | 1,701,737 | 1,471,806 | 1.5 M to 1.5 M (-2.34 %) |
Nov 13 2006 | NRPH | NEW RIVER PHARMACE ... | KIRK RANDAL J | Chairman, President ... | Sell | S | 49.01 | 54,887 | 2,690,045 | 1,507,090 | 1.6 M to 1.5 M (-3.51 %) |
Nov 13 2006 | NRPH | NEW RIVER PHARMACE ... | KIRK RANDAL J | Chairman, President ... | Sell | S | 48.23 | 138,198 | 6,665,248 | 5,764,637 | 5.9 M to 5.8 M (-2.34 %) |
Nov 13 2006 | NRPH | NEW RIVER PHARMACE ... | KIRK RANDAL J | Chairman, President ... | Sell | S | 49.01 | 214,975 | 10,536,054 | 5,902,835 | 6.1 M to 5.9 M (-3.51 %) |
Nov 13 2006 | NRPH | NEW RIVER PHARMACE ... | KIRK RANDAL J | Chairman, President ... | Sell | S | 48.23 | 35,151 | 1,695,322 | 1,466,218 | 1.5 M to 1.5 M (-2.34 %) |
Nov 13 2006 | NRPH | NEW RIVER PHARMACE ... | KIRK RANDAL J | Chairman, President ... | Sell | S | 49.01 | 54,678 | 2,679,802 | 1,501,369 | 1.6 M to 1.5 M (-3.51 %) |
Nov 13 2006 | NRPH | NEW RIVER PHARMACE ... | KIRK RANDAL J | Chairman, President ... | Sell | S | 48.23 | 105,849 | 5,105,066 | 4,415,278 | 4.5 M to 4.4 M (-2.34 %) |
Nov 13 2006 | NRPH | NEW RIVER PHARMACE ... | KIRK RANDAL J | Chairman, President ... | Sell | S | 49.01 | 164,655 | 8,069,840 | 4,521,127 | 4.7 M to 4.5 M (-3.51 %) |
Nov 13 2006 | NRPH | NEW RIVER PHARMACE ... | KIRK RANDAL J | Chairman, President ... | Sell | S | 48.23 | 28,353 | 1,367,457 | 1,182,665 | 1.2 M to 1.2 M (-2.34 %) |
Nov 13 2006 | NRPH | NEW RIVER PHARMACE ... | KIRK RANDAL J | Chairman, President ... | Sell | S | 49.01 | 44,104 | 2,161,564 | 1,211,018 | 1.3 M to 1.2 M (-3.51 %) |
Nov 13 2006 | NRPH | NEW RIVER PHARMACE ... | KIRK RANDAL J | Chairman, President ... | Sell | S | 48.23 | 35,916 | 1,732,218 | 1,498,144 | 1.5 M to 1.5 M (-2.34 %) |
Nov 13 2006 | NRPH | NEW RIVER PHARMACE ... | KIRK RANDAL J | Chairman, President ... | Sell | S | 49.01 | 55,868 | 2,738,124 | 1,534,060 | 1.6 M to 1.5 M (-3.51 %) |
Nov 13 2006 | NRPH | NEW RIVER PHARMACE ... | KIRK RANDAL J | Chairman, President ... | Sell | S | 48.23 | 12,554 | 605,476 | 523,650 | 536.2 K to 523.7 K (-2.34 %) |
Nov 13 2006 | NRPH | NEW RIVER PHARMACE ... | KIRK RANDAL J | Chairman, President ... | Sell | S | 49.01 | 19,528 | 957,079 | 536,204 | 555.7 K to 536.2 K (-3.51 %) |
Dec 11 2006 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Buy | P | 6.16 | 80,000 | 492,800 | 1,262,000 | 1.2 M to 1.3 M (+6.77 %) |
Dec 11 2006 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Buy | P | 5.55 | 336,200 | 1,865,910 | 1,182,000 | 845.8 K to 1.2 M (+39.75 %) |
Dec 06 2006 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Buy | P | 2.84 | 53,500 | 151,940 | 845,800 | 792.3 K to 845.8 K (+6.75 %) |
Dec 06 2006 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Buy | P | 2.86 | 11,500 | 32,890 | 792,300 | 780.8 K to 792.3 K (+1.47 %) |
Sep 18 2006 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Buy | P | 2.50 | 102,500 | 256,250 | 780,800 | 678.3 K to 780.8 K (+15.11 %) |
Sep 18 2006 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Buy | P | 2.50 | 20,000 | 50,000 | 678,300 | 658.3 K to 678.3 K (+3.04 %) |
Sep 13 2006 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Buy | P | 2.50 | 74,000 | 185,000 | 658,300 | 584.3 K to 658.3 K (+12.66 %) |
Sep 13 2006 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Buy | P | 2.58 | 20,000 | 51,600 | 584,300 | 564.3 K to 584.3 K (+3.54 %) |
Sep 13 2006 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Buy | P | 2.54 | 3,200 | 8,128 | 564,300 | 561.1 K to 564.3 K (+0.57 %) |
Sep 08 2006 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Buy | P | 2.52 | 30,500 | 76,860 | 561,100 | 530.6 K to 561.1 K (+5.75 %) |
Sep 08 2006 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Buy | P | 2.51 | 15,000 | 37,650 | 530,600 | 515.6 K to 530.6 K (+2.91 %) |
Sep 08 2006 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Buy | P | 2.56 | 17,300 | 44,288 | 515,600 | 498.3 K to 515.6 K (+3.47 %) |
Aug 29 2006 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Buy | P | 2.60 | 23,000 | 59,800 | 498,300 | 475.3 K to 498.3 K (+4.84 %) |
Aug 29 2006 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Buy | P | 2.56 | 60,000 | 153,600 | 475,300 | 415.3 K to 475.3 K (+14.45 %) |
Aug 29 2006 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Buy | P | 2.50 | 110,900 | 277,250 | 415,300 | 304.4 K to 415.3 K (+36.43 %) |
Aug 24 2006 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Buy | P | 2.50 | 93,300 | 233,250 | 304,400 | 211.1 K to 304.4 K (+44.20 %) |
Aug 24 2006 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Buy | P | 2.49 | 6,700 | 16,683 | 211,100 | 204.4 K to 211.1 K (+3.28 %) |
Aug 24 2006 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Buy | P | 2.46 | 17,600 | 43,296 | 204,400 | 186.8 K to 204.4 K (+9.42 %) |
Aug 21 2006 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Buy | P | 2.46 | 12,500 | 30,750 | 186,800 | 174.3 K to 186.8 K (+7.17 %) |
Aug 21 2006 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Buy | P | 2.42 | 3,500 | 8,470 | 174,300 | 170.8 K to 174.3 K (+2.05 %) |
Aug 21 2006 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Buy | P | 2.46 | 94,100 | 231,486 | 170,800 | 76.7 K to 170.8 K (+122.69 %) |
Sep 25 2006 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Grant | A | 0.00 | 10,800 | 0 | 1,066,991 | 1.1 M to 1.1 M (+1.02 %) |
Sep 15 2006 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Buy | P | 15.42 | 30,571 | 471,405 | 642,834 | 612.3 K to 642.8 K (+4.99 %) |
Sep 08 2006 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Buy | P | 14.95 | 42,000 | 627,900 | 612,263 | 570.3 K to 612.3 K (+7.37 %) |
Aug 29 2006 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Buy | P | 15.00 | 12,621 | 189,315 | 570,263 | 557.6 K to 570.3 K (+2.26 %) |
Aug 29 2006 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Buy | P | 15.07 | 13,990 | 210,829 | 557,642 | 543.7 K to 557.6 K (+2.57 %) |
Aug 29 2006 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Buy | P | 13.48 | 7,697 | 103,756 | 543,652 | 536 K to 543.7 K (+1.44 %) |
Aug 24 2006 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Buy | P | 13.17 | 10,693 | 140,827 | 535,955 | 525.3 K to 536 K (+2.04 %) |
Aug 24 2006 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Buy | P | 12.97 | 12,500 | 162,125 | 525,262 | 512.8 K to 525.3 K (+2.44 %) |
Aug 24 2006 | NOVI | CLINICAL DATA INC | KIRK RANDAL J | Director | Buy | P | 12.30 | 4,012 | 49,348 | 512,762 | 508.8 K to 512.8 K (+0.79 %) |
Apr 21 2006 | NRPH | NEW RIVER PHARMACE ... | KIRK RANDAL J | Chairman, President ... | Sell | S | 33.50 | 70,684 | 2,367,914 | 1,561,977 | 1.6 M to 1.6 M (-4.33 %) |
Apr 21 2006 | NRPH | NEW RIVER PHARMACE ... | KIRK RANDAL J | Chairman, President ... | Sell | S | 33.50 | 276,847 | 9,274,375 | 6,117,810 | 6.4 M to 6.1 M (-4.33 %) |
Apr 21 2006 | NRPH | NEW RIVER PHARMACE ... | KIRK RANDAL J | Chairman, President ... | Sell | S | 33.50 | 70,415 | 2,358,903 | 1,556,047 | 1.6 M to 1.6 M (-4.33 %) |
Apr 21 2006 | NRPH | NEW RIVER PHARMACE ... | KIRK RANDAL J | Chairman, President ... | Sell | S | 33.50 | 212,044 | 7,103,474 | 4,685,782 | 4.9 M to 4.7 M (-4.33 %) |
Apr 21 2006 | NRPH | NEW RIVER PHARMACE ... | KIRK RANDAL J | Chairman, President ... | Sell | S | 33.50 | 56,798 | 1,902,733 | 1,255,122 | 1.3 M to 1.3 M (-4.33 %) |
Apr 21 2006 | NRPH | NEW RIVER PHARMACE ... | KIRK RANDAL J | Chairman, President ... | Sell | S | 33.50 | 71,948 | 2,410,258 | 1,589,928 | 1.7 M to 1.6 M (-4.33 %) |
Apr 21 2006 | NRPH | NEW RIVER PHARMACE ... | KIRK RANDAL J | Chairman, President ... | Sell | S | 33.50 | 25,148 | 842,458 | 555,732 | 580.9 K to 555.7 K (-4.33 %) |